Trial Profile

A Phase Ia/Ib, First-in-Human, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Efficacy of SG2501 in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 21 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SG 2501 (Primary)
Indications Amyloid light-chain amyloidosis; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
Focus Adverse reactions; First in man
Sponsors Hangzhou Sumgen Biotech

18 Mar 2025 Status changed from recruiting to discontinued.
10 Feb 2023 Planned End Date changed from 1 Sep 2024 to 30 Apr 2025.
10 Feb 2023 Planned primary completion date changed from 1 Feb 2023 to 30 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com